Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 3 2Phase 2 1

Status

Completed 3Active not recruiting 2Recruiting 1

Sponsor Class

INDUSTRY 6OTHER 3

Study Type

Interventional 6

Sponsor

Cancer Type

Tumor-Agnostic 5Gynecologic 1

Conditions

Ovarian Neoplasms 9Fallopian Tube Neoplasms 8Neoplasms 6Prostatic Neoplasms 5Carcinoma, Ovarian Epithelial 5Recurrence 3Pancreatic Neoplasms 3Breast Neoplasms 3Urinary Bladder Neoplasms 2Metastatic Castration Resistant Prostate Cancer 2Colorectal Neoplasms 2Carcinoma, Transitional Cell 2Uterine Cervical Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Solid Tumor 1Sarcoma 1Primary Myelofibrosis 1Pathologic Complete Response 1Neoplasm Metastasis 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Multiple Myeloma 1Mental Retardation, X-Linked, With Or Without Seizures, Arx-Related 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Lung Neoplasms 1

Interventions

pembrolizumab 133Gemcitabine 101Paclitaxel 100Carboplatin 84Nivolumab 66Docetaxel 62Bevacizumab 62Cisplatin 57Pemetrexed 50Fluorouracil 49Cyclophosphamide 41Cetuximab 41trametinib 38venetoclax 37Leucovorin 37Irinotecan 37Sorafenib 35Capecitabine 35Ipilimumab 33Dexamethasone 32atezolizumab 31Erlotinib Hydrochloride 28130-nm albumin-bound paclitaxel 28Drug Therapy 27Epoetin Alfa 26Doxorubicin 25Oxaliplatin 24Albumin-Bound Paclitaxel 24Prednisone 23Rituximab 22

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
INDUSTRY × Neoplasms × rucaparib × Clear all
NCT03899155 2026-06-03

Pan Tumor Rollover Study

Bristol-Myers Squibb

Phase 2 Recruiting
1,500 enrolled
Tumor-Agnostic

Neoplasms

NCT03768063 2026-04-28

IMbrella B

Hoffmann-La Roche

Phase 3 Active not recruiting
1,000 enrolled
Tumor-Agnostic

Neoplasms

NCT03522246 2025-06-24

ATHENA

pharmaand GmbH

Phase 3 Active not recruiting
1,097 enrolled 26 charts
Gynecologic

Carcinoma, Ovarian Epithelial, Pathologic Complete Response, Fallopian Tube Neoplasms, Neoplasms

NCT02740712 2023-06-09

DDI

pharmaand GmbH

Phase 1 Completed
17 enrolled
Tumor-Agnostic

Neoplasms

NCT03521037 2023-06-09

Rucaparib Hepatic Impairment Study in Patients With a Solid Tumor

pharmaand GmbH

Phase 1 Completed
16 enrolled
Tumor-Agnostic

Neoplasms

NCT03954366 2023-06-08

Drug-Drug Interaction Study of Rucaparib, Rosuvastatin and Oral Contraceptives

pharmaand GmbH

Phase 1 Completed
36 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡